Research Article
Interleukin-18 in Brazilian Rheumatoid Arthritis Patients: Can Leflunomide Reduce It?
Table 1
Clinical and laboratory data for the RA and CG groups.
| Data | RA | CG | |
| Sample n (%) | 140 | 40 | 0.0657 | Female | 130 (92.8%) | 33 (82.5%) | | Male | 10 (7.2%) | 7 (17.5%) | |
| Age in years, mean ± SEM | 54.0 (±12.0) | 51.5 (±8.5) | 0,0943 | Race and ethnicity classifications | | | | Indigenous | 1 | 0 | ns | Multiracial | 49 | 9 | ns | Black or African American | 60 | 22 | ns | White | 30 | 9 | ns |
| Disease duration, years, mean ± SEM | 10.0 (±7.8) | | | + rheumatoid factor (n%) | 113 (80.7%) | | | ESR mm/h, median, (range) | 36 (2–125) | | | Disease classification (n%) | | | | CDAI, mean ± SEM | 18.5 (±13.0) | | | Low disease activity (≤10) | 45 (32%) | | | Moderate and high disease activity (>10) | 95 (68%) | | | DAS28 mean ± SEM | 4.5 (±1.5) | | | Low disease activity (≤3.2) | 31 (22.2%) | | | Moderate and high disease activity (>3.2) | 109 (77.8%) | | |
| Treatment (n) | | | | None (naïve for treatment) | 60 | | | Prednisone only | 11 | | | Methotrexate only | 12 | | | Leflunomide only | 7 | | | More than one treatment | 50 | | |
| Comorbidities (n) | | | | None | 109 | | | Diabetes mellitus | 9 | | | Obesity | 6 | | | Osteoporosis | 12 | | | Systemic arterial hypertension | 24 | | |
|
|
CG- control group; SEM- standard error of mean; ESR- erythrocyte sedimentation rate.
|